Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Liabilities (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Total Liabilities for 15 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 22.09% year-over-year to $1.4 billion, compared with a TTM value of $1.4 billion through Dec 2025, up 22.09%, and an annual FY2025 reading of $1.4 billion, up 22.09% over the prior year.
  • Total Liabilities was $1.4 billion for Q4 2025 at Neurocrine Biosciences, up from $1.3 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.4 billion in Q4 2025 and bottomed at $640.8 million in Q1 2021.
  • Average Total Liabilities over 4 years is $940.4 million, with a median of $846.1 million recorded in 2023.
  • The sharpest move saw Total Liabilities decreased 3.87% in 2021, then skyrocketed 60.86% in 2024.
  • Year by year, Total Liabilities stood at $671.3 million in 2021, then soared by 51.85% to $1.0 billion in 2023, then rose by 10.75% to $1.1 billion in 2024, then increased by 22.09% to $1.4 billion in 2025.
  • Business Quant data shows Total Liabilities for NBIX at $1.4 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.2 billion in Q2 2025.